問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Infectious Disease

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

National Taiwan University Cancer Center

Division of General Internal Medicine

更新時間：2025-03-04

余忠仁Yu, Chong-Jen
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -4 個月

Recruiting Trial

170Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

余忠仁

List

358Cases

2026-02-26 - 2028-04-30

Phase II

Not yet recruiting
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    注射用凍晶粉末

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2024-07-01 - 2025-02-18

Phase I/II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2026-03-16 - 2031-11-30

Phase II

Not yet recruiting
A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER

  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    注射劑 注射劑 注射劑

Participate Sites
4Sites

Recruiting4Sites

2026-03-30 - 2032-08-31

Phase II

Active
A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

  • Condition/Disease

    Small Cell Lung Cancer (SCLC)

  • Test Drug

    輸注液 輸注液 輸注液

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2026-04-01 - 2029-11-30

Phase III

Active
DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

  • Condition/Disease

    Small Cell Lung Cancer (SCLC) 、Extensive-stage Small Cell Lung Cancer (ES-SCLC)

  • Test Drug

    N/A N/A N/A N/A N/A

Participate Sites
6Sites

Not yet recruiting6Sites

2024-10-01 - 2034-06-01

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2024-10-01 - 2032-12-31

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2024-11-29 - 2029-03-02

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2024-11-27 - 2028-05-29

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2025-01-01 - 2028-12-31

Others

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Not yet recruiting2Sites

1 5 6 7 8 9 36
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB